BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

348 related articles for article (PubMed ID: 11602747)

  • 1. Replication-competent or attenuated, nonpropagating vesicular stomatitis viruses expressing respiratory syncytial virus (RSV) antigens protect mice against RSV challenge.
    Kahn JS; Roberts A; Weibel C; Buonocore L; Rose JK
    J Virol; 2001 Nov; 75(22):11079-87. PubMed ID: 11602747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Attenuated Human Parainfluenza Virus Type 1 (HPIV1) Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus (RSV) as a Bivalent HPIV1/RSV Vaccine.
    Mackow N; Amaro-Carambot E; Liang B; Surman S; Lingemann M; Yang L; Collins PL; Munir S
    J Virol; 2015 Oct; 89(20):10319-32. PubMed ID: 26223633
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.
    van den Pol AN; Mao G; Chattopadhyay A; Rose JK; Davis JN
    J Virol; 2017 Mar; 91(6):. PubMed ID: 28077641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coexpression of respiratory syncytial virus (RSV) fusion (F) protein and attachment glycoprotein (G) in a vesicular stomatitis virus (VSV) vector system provides synergistic effects against RSV infection in a cotton rat model.
    Brakel KA; Binjawadagi B; French-Kim K; Watts M; Harder O; Ma Y; Li J; Niewiesk S
    Vaccine; 2021 Nov; 39(47):6817-6828. PubMed ID: 34702618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant vesicular stomatitis virus expressing respiratory syncytial virus (RSV) glycoproteins: RSV fusion protein can mediate infection and cell fusion.
    Kahn JS; Schnell MJ; Buonocore L; Rose JK
    Virology; 1999 Feb; 254(1):81-91. PubMed ID: 9927576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
    Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
    Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.
    Majid AM; Ezelle H; Shah S; Barber GN
    J Virol; 2006 Jul; 80(14):6993-7008. PubMed ID: 16809305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alphavirus replicon particles encoding the fusion or attachment glycoproteins of respiratory syncytial virus elicit protective immune responses in BALB/c mice and functional serum antibodies in rhesus macaques.
    Elliott MB; Chen T; Terio NB; Chong SY; Abdullah R; Luckay A; Egan MA; Boutilier LA; Melville K; Lerch RA; Long D; Eldridge JH; Parks CL; Udem SA; Hancock GE
    Vaccine; 2007 Oct; 25(41):7132-44. PubMed ID: 17850933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chimeric subgroup A respiratory syncytial virus with the glycoproteins substituted by those of subgroup B and RSV without the M2-2 gene are attenuated in African green monkeys.
    Cheng X; Zhou H; Tang RS; Munoz MG; Jin H
    Virology; 2001 Apr; 283(1):59-68. PubMed ID: 11312662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric bovine respiratory syncytial virus with glycoprotein gene substitutions from human respiratory syncytial virus (HRSV): effects on host range and evaluation as a live-attenuated HRSV vaccine.
    Buchholz UJ; Granzow H; Schuldt K; Whitehead SS; Murphy BR; Collins PL
    J Virol; 2000 Feb; 74(3):1187-99. PubMed ID: 10627529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection against lethal vaccinia virus challenge by using an attenuated matrix protein mutant vesicular stomatitis virus vaccine vector expressing poxvirus antigens.
    Braxton CL; Puckett SH; Mizel SB; Lyles DS
    J Virol; 2010 Apr; 84(7):3552-61. PubMed ID: 20089648
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Priming and boosting immunity to respiratory syncytial virus by recombinant replication-defective vaccinia virus MVA.
    Wyatt LS; Whitehead SS; Venanzi KA; Murphy BR; Moss B
    Vaccine; 1999 Oct; 18(5-6):392-7. PubMed ID: 10519927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmid DNA encoding the respiratory syncytial virus G protein is a promising vaccine candidate.
    Li X; Sambhara S; Li CX; Ettorre L; Switzer I; Cates G; James O; Parrington M; Oomen R; Du RP; Klein M
    Virology; 2000 Mar; 269(1):54-65. PubMed ID: 10725198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of recombinant respiratory syncytial viruses with the region responsible for type 2 T-cell responses and pulmonary eosinophilia deleted from the attachment (G) protein.
    Elliott MB; Pryharski KS; Yu Q; Boutilier LA; Campeol N; Melville K; Laughlin TS; Gupta CK; Lerch RA; Randolph VB; LaPierre NA; Dack KM; Hancock GE
    J Virol; 2004 Aug; 78(16):8446-54. PubMed ID: 15280453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-propagating, recombinant vesicular stomatitis virus vectors encoding respiratory syncytial virus proteins generate potent humoral and cellular immunity against RSV and are protective in mice.
    Johnson JE; McNeil LK; Megati S; Witko SE; Roopchand VS; Obregon JH; Illenberger DM; Kotash CS; Nowak RM; Braunstein E; Yurgelonis I; Jansen KU; Kalyan NK; Sidhu MK
    Immunol Lett; 2013 Feb; 150(1-2):134-44. PubMed ID: 23261719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of a vesicular stomatitis virus complementation system to analyze respiratory syncytial virus binding.
    Klenk K; Roberts SR
    Virus Res; 2002 Dec; 90(1-2):327-35. PubMed ID: 12457986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of nonpathogenic, live, viral vaccine vectors inducing potent cellular immune responses.
    Publicover J; Ramsburg E; Rose JK
    J Virol; 2004 Sep; 78(17):9317-24. PubMed ID: 15308726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.